Memorial Hospital Research Laboratories
The Britta Weigelt Lab
Gynecology DMT Research Laboratory
Our laboratory focuses on the use of high-throughput genomics and functional genomics to identify drivers of rare gynecologic cancer types, and to define the clinical and biological significance of intra-tumor phenotypic and genetic heterogeneity in these tumors. Dr. Weigelt’s laboratory is devising strategies to overcome the challenges posed by intra-tumor genetic heterogeneity, based on state-of-the-art sequencing analyses of circulating cell free (cf)DNA and of single cells. By bringing together traditional pathological techniques with genetic analyses and functional studies, the Weigelt lab seeks to refine the classification of gynecologic cancers and identify novel drivers and potential therapeutic targets of specific tumor types. In addition, Dr. Weigelt is investigating if cfDNA analysis (so-called “liquid biopsies”) can accurately monitor the disease course of women with endometrial or cervical cancer, and if resistance mechanisms to platinum salts or PARP inhibitors in ovarian cancer patients can be identified in cfDNA.
Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Kim SH, Da Cruz Paula A, Basili T, Dopeso H, Bi R, Pareja F, da Silva EM, Gularte-Mérida R, Sun Z, Fujisawa S, Smith CG, Ferrando L, Martins Sebastião AP, Bykov Y, Li A, Silveira C, Ashley CW, Stylianou A, Selenica P, Samore WR, Jungbluth AA, Zamarin D, Abu-Rustum NR, Helin K, Soslow RA, Reis-Filho JS, Oliva E, Weigelt B. Nat Commun 2020; 11:44. doi: 10.1038/s41467-019-13806-x.
Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Clin Cancer Res 2017; 23:6708-6720. doi: 10.1158/1078-0432.CCR-17-0544
Britta Weigelt, PhD
Director, Gynecology DMT Research Laboratory
- Molecular geneticist Britta Weigelt studies the genomics of gynecologic cancers and the use of circulating cell-free DNA for disease monitoring and the identification of therapy resistance mechanisms.
- B.S. Biomedical Engineering, Drexel University
- M.D. Drexel University College of Medicine
- M.Sc. Clinical Epidemiology and Health Services Research, Weill Cornell Graduate School of Medical Sciences
- Residency Obstetrics and Gynecology, Albany Medical Center
- BA, Neurobiology and Behavior, Cornell University
- MD, Virginia Commonwealth University School of Medicine
- Internship, Obstetrics and Gynecology, University of Washington
- Residency, Obstetrics and Gynecology, New York Presbyterian- Weill Cornell Medical Center
- BS, Life Science, The Pennsylvania State University
- MD, Sidney Kimmel Medical College at Thomas Jefferson University
- • Gynecologic Surgery and Obstetrics Residency, Walter Reed National Military Medical Center – National Capital Consortium
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Britta Weigelt discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.